Identifying Drug-Drug Interactions in Diabetic Patients with Chronic Kidney Disease: Pharmacist’s Interventions
Pharmaceutical Science-Pharmacy Practice
DOI:
https://doi.org/10.22376/ijlpr.2023.13.1.P105-112Keywords:
Drug-Drug Interaction, Diabetes Mellitus, Chronic Kidney Disease, and Pharmacist’s InterventionAbstract
Drug-drug interactions (DDIs) can negatively affect patients ‘therapeutic outcomes. Therefore, our aim was to evaluate DDIs among diabetic patients with chronic kidney disease (CKD). To achieve this aim, our objectives were to identify DDIs in diabetic patients with CKD admitted to the Medicine Department of the tertiary care hospital and to evaluate pharmacist’s interventions in managing DDIs among these patients. A prospective observational study was conducted over 6 months. The pharmacist performed a medication chart review, and DDIs were identified by using Lexicomp® drug interaction. The pharmacist informed prescribers regarding the occurrence of DDIs, and all pharmacist`s interventions were classified according to Pharmaceutical Care Network Europe. Overall 307 DDIs were identified among a total of 119 study patients with an average of 2.6 DDIs per patient. The most of identified DDIs (205, 66.7%) belonged to the interaction risk-rating category of C, which indicates that DDIs required close monitoring of patients’ therapy to avoid any potential adverse outcome. DDIs that needed to be managed by considering therapy modification (risk-rating category of D) and avoiding drug combination (risk-rating category of X) were accounted for 19.2% and 14.0% of all detected interactions, respectively. Interactions between Furosemide–Insulin (43, 14.0%), Amlodipine–Calcium carbonate/vitamin D3 (35, 11.4%) were found to be among most commonly identified DDIs. The pharmacist delivered different types of interventions to prescribers, which ranged from monitoring of therapy outcome to stopping DDIs. A great proportion of delivered pharmacist’s interventions (87%) were accepted by prescribers. Clinically significant DDIs occurred commonly in hospitalized diabetic patients with CKD. The pharmacist delivered important interventions in timely identifying DDIs.
References
Sun X, Yu W, Hu C. Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application. BioMed Res Int. 2014;2014:926713. doi: 10.1155/2014/926713, PMID 24864266.
Kaul N, Ali S. Genes, genetics, and environment in Type 2 diabetes: implication in personalized medicine. DNA Cell Biol. 2016;35(1):1-12. doi: 10.1089/dna.2015.2883, PMID 26495765.
Saisho Y. Importance of beta cell function for the treatment of Type 2 diabetes. J Clin Med. 2014;3(3):923-43. doi: 10.3390/jcm3030923, PMID 26237486.
WHO Diabetes Programme, WHO; 2019 [cited Jan 27 2019]. Available from: https://www.who.int/diabetes/en/.
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-45. doi: 10.2215/CJN.11491116, PMID 28522654.
Guido Gembillo, Ylenia Ingrasciotta, Salvatore Crisafulli, Nicoletta Luxi, Rossella Siligato, Domenico Santoro, et al. Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia. Int J Mol Sci. 2021; 22(9): 4824. doi: 10.3390/ijms22094824.
Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM et al. Chronic kidney disease: A public health problem that needs a public health action plan. Prev Chronic Dis. 2006;3(2):A57. PMID 16539798.
Fraser SDS, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, et al. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. BMC Nephrol. 2015;16:193. doi: 10.1186/s12882-015-0189-z, PMID 26620131.
Shippee ND, Shah ND, May CR, Mair FS, Montori VM. Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. J Clin Epidemiol. 2012;65(10):1041-51. doi: 10.1016/j.jclinepi.2012.05.005, PMID 22910536.
Njeri LW, Ogallo WO, Nyamu DG, Opanga SA, Birichi AR. Medication-related problems among adult chronic kidney disease patients in a sub-Saharan tertiary hospital. Int J Clin Pharm. 2018;40(5):1217-24. doi: 10.1007/s11096-018-0651-7, PMID 29766391.
Patel HR, Pruchnicki MC, Hall LE. Assessment for chronic kidney disease service in high-risk patients at community health clinics. Ann Pharmacother. 2005;39(1):22-7. doi: 10.1345/aph.1E269, PMID 15546945.
Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical pharmacokinetics in kidney disease: fundamental principles. Clin J Am Soc Nephrol. 2018;13(7):1085-95. doi: 10.2215/CJN.00340118, PMID 29934432.
Keller F, Hann A. Clinical pharmacodynamics: principles of drug response and alterations in kidney disease. Clin J Am Soc Nephrol. 2018;13(9):1413-20. doi: 10.2215/CJN.10960917, PMID 29769182.
Grabe DW, Low CL, Bailie GR, Eisele G. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol. 1997;47(2):117-21. PMID 9049460.
Allenet B, Chen C, Romanet T, Vialtel P, Calop J. Assessing a pharmacist-run anaemia educational programme for patients with chronic renal insufficiency. Pharm World Sci. 2007;29(1):7-11. doi: 10.1007/s11096-005-4800-4, PMID 17268940.
Jiang S-P, Zhu ZY, Wu X-L, Lu X-Y, Zhang XG, Wu B-H. Effectiveness of pharmacist dosing adjustment for critically ill patients receiving continuous renal replacement therapy: a comparative study. Ther Clin Risk Manag. 2014;10:405-12. doi: 10.2147/TCRM.S59187, PMID 24940066.
Moyen E, Camiré E, Stelfox HT. Clinical review: medication errors in critical care. Crit Care. 2008;12(2):208. doi: 10.1186/cc6813, PMID 18373883.
Rama M, Viswanathan G, Acharya LD, Attur RP, Reddy PN, Raghavan SV. Assessment of drug-drug interactions among renal failure patients of nephrology ward in a South Indian tertiary Care Hospital. Indian J Pharm Sci. 2012;74(1):63-8. doi: 10.4103/0250-474X.102545, PMID 23204624.
Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:A0828. HERO ID: 658418.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2);Suppl 1:S1-266. PMID 11904577.
Pharmaceutical Care Network. Europe. Classification for drug related problems version 8.02; 2017. Available from: https://www.pcne.org/upload/files/230_PCNE_classification_V8-02.pdf.
Saleem A, Masood I, Khan TM. Clinical relevancy and determinants of potential drug-drug interactions in chronic kidney disease patients: results from a retrospective analysis. Integr Pharm Res Pract. 2017;6:71-7. doi: 10.2147/IPRP.S128816, PMID 29354553.
Mason NA, Bakus JL. Strategies for reducing polypharmacy and other medication-related problems in chronic kidney disease. Semin Dial. 2010;23(1):55-61. doi: 10.1111/j.1525-139X.2009.00629.x, PMID 19747171.
Kimura H, Tanaka K, Saito H, Iwasaki T, Oda A, Watanabe S, et al. Association of polypharmacy with kidney disease progression in adults with CKD. Clin J Am Soc Nephrol. 2021;16(12):1797-804. doi: 10.2215/CJN.03940321, PMID 34782408.
Dobrică E-C, Găman M-A, Cozma M-A, Bratu OG, Pantea Stoian AP, Diaconu CC. Polypharmacy in type 2 diabetes mellitus: insights from an internal medicine department. Medicina (Kaunas). 2019;55(8):436. doi: 10.3390/medicina55080436, PMID 31382651.
Dimitriadis G, Leighton B, Parry-Billings M, Tountas C, Raptis S, Newsholme EA. Furosemide decreases the sensitivity of glucose transport to insulin in skeletal muscle in vitro. Eur J Endocrinol. 1998;139(1):118-22. doi: 10.1530/eje.0.1390118, PMID 9703388.
Salerno DM, Anderson B, Sharkey PJ, Iber C. Intravenous verapamil for treatment of multifocal atrial tachycardia with and without calcium pretreatment. Ann Intern Med. 1987;107(5):623-8. doi: 10.7326/0003-4819-107-5-623, PMID 3662276.
Marquito AB, Fernandes NM, Colugnati FA, de Paula RB. Identifying potential drug interactions in chronic kidney disease patients. J Bras Nefrol. 2014;36(1):26-34. doi: 10.5935/0101-2800.20140006, PMID 24676611.
Fasipe OJ, Akhideno PE, Nwaiwu O, Adelosoye AA. Assessment of prescribed medications and pattern of distribution for potential drugdrug interactions among chronic kidney disease patients attending the Nephrology Clinic of Lagos University Teaching Hospital in Sub- Saharan West Africa. Clin Pharmacol. 2017;9:125-32. doi: 10.2147/CPAA.S147835, PMID 29123429.
American College of Clinical Pharmacy, McBane SE, Dopp AL, Abe A, Benavides S, Chester EA, et al. Collaborative drug therapy management and comprehensive medication management-2015. Pharmacotherapy. 2015;35(4):e39-50. doi: 10.1002/phar.1563, PMID 25884536.
Jorgenson D, Dalton D, Farrell B, Tsuyuki RT, Dolovich L. Guidelines for pharmacists integrating into primary care teams. Can Pharm J (Ott). 2013;146(6):342-52. doi: 10.1177/1715163513504528, PMID 24228050.
Ghaibi S, Ipema H, Gabay M, American Society of Health System Pharmacists. ASHP guidelines on the pharmacist’s role in providing drug information. Am J Health Syst Pharm. 2015;72(7):573-7. doi: 10.2146/sp150002, PMID 25788512.
Sisson E, Kuhn C. Pharmacist roles in the management of patients with type 2 diabetes. J Am Pharm Assoc (2003). 2009;49;Suppl 1:S41-5. doi: 10.1331/JAPhA.2009.09075, PMID 19801364.
Fazel MT, Bagalagel A, Lee JK, Martin JR, Slack MK. Impact of diabetes care by pharmacists as part of health care team in ambulatory settings: A systematic review and meta-analysis. Ann Pharmacother. 2017;51(10):890-907. doi: 10.1177/1060028017711454, PMID 28573873.
Al Raiisi FAl, Stewart D, Fernandez-Llimos F, Salgado TM, Mohamed MF, Cunningham S. Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review. Int J Clin Pharm. 2019;41(3):630-66. doi: 10.1007/s11096-019-00816-4, PMID 30963447.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Armita Sabahi, Namitha K. B
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
